A mathematical approach for assessing the transport of large neutral amino acids across the blood-brain barrier in man

• Autorzy: Dahl R.H. , Berg R.M.G.
• Języki publikacji: EN

Abstrakty

EN

Changes in the large neutral amino acid (LNAA) transport across the blood-brain barrier (BBB) is thought to contribute to brain dysfunction in a number of clinical conditions, including phenylketonuria, acute liver failure, and sepsis. Here, we present a novel approach for estimating BBB permeability and the LNAA concentrations in brain extracellular fluid, by demonstrating that they can be mathematically derived on the basis of kinetic constants of the BBB available from the literature, if cerebral blood flow and the arterial and jugular venous LNAA concentrations are known. While it is well known that the permeability surface area product of the BBB to a LNAA from blood to brain (PS1) can be calculated from the arterial LNAA concentrations and kinetic constants of the BBB, we demonstrate that the permeability surface area product from brain to blood (PS2) can be calculated by deriving the substrate activity of the saturable transporter from the kinetic constants and arterial and jugular venous LNAA concentrations, and that the concentration of the LNAA in brain extracellular fluid can then be determined. This approach is methodically simple, and may be useful for assessing the transcerebral exchange kinetics of LNAAs in future human-experimental and clinical studies.

Słowa kluczowe

EN

mathematical method; assessing; transport; amino acid; aromatic amino acid; kinetics; permeability; neurotransmitter; blood-brain barrier; man

• Wydawca: -
• Czasopismo: Acta Neurobiologiae Experimentalis
• Rocznik: 2015
• Tom: 75
• Numer: 4
• Opis fizyczny: p.446-456,fig.,ref.

Twórcy

autor

Dahl R.H.

• Neurointensive Care Unit 2093, Department of Neuroanaesthesiology, University Hospital Rigshospitalet, Copenhagen, Denmark

autor

Berg R.M.G.

• Department of Clinical Physiology and Nuclear Medicine, Bispebjerg and Frederiksberg Hospitals, Frederiksberg, Denmark

Bibliografia

• Aksoy FG, Lev MH (2000) Dynamic contrast-enhanced brain perfusion imaging: technique and clinical applications. Semin Ultrasound CT MR 21: 462–477.
• Basler T, Meier-Hellmann A, Bredle D, Reinhart K (2002) Amino acid imbalance early in septic encephalopathy. Intensive Care Med 28: 293–298.
• Begley DJ (1998) In situ brain perfusion. In: Introduction to the Blood-Brain Barrier: Methodology, Biology and Pathology (Pardridge WM, Ed.). Cambridge University Press, Cambridge, UK.
• Berg RMG, Taudorf S, Bailey DM, Lundby C, Larsen FS, Pedersen BK, Møller K (2010) Cerebral net exchange of large neutral amino acids after lipopolysaccharide infusion in healthy humans. Crit Care 14: R16.
• Bower RH, Muggia-Sullam M, Vallgren S, Hurst JM, Kern KA, LaFrance R, Fischer JE (1986) Branched chain amino acid-enriched solutions in the septic patient. A randomized, prospective trial. Ann Surg 203: 13–20.
• Carroll TJ, Teneggi V, Jobin M, Squassante L, Treyer V, Hany TF, Burger C, Wang L, Bye A, Von Schulthess GK, Buck A (2002) Absolute quantification of cerebral blood flow with magnetic resonance, reproducibility of the method, and comparison with H2O15 positron emission tomography. J Cereb Blood Flow Metab 22: 1149– 1156.
• Choi TB, Pardridge WM (1986) Phenylalanine transport at the human blood-brain barrier. Studies with isolated human brain capillaries. J Biol Chem 261: 6536–6541.
• Crone C (1963) The permeability of capillaries in various organs as determined by use of the ‘indicator diffusion’ method. Acta Physiol Scand 58: 292–305.
• Dejong CH, van de Poll MC, Soeters PB, Jalan R, Damink SW (2007) Aromatic amino acid metabolism during liver failure. J Nutr 137: 1579S–1585S.
• Elkind JA, Lim MM, Johnson BN, Palmer CP, Putnam BJ, Kirschen MP, Cohen AS (2015) Efficacy, dosage, and duration of action of branched chain amino Acid therapy for traumatic brain injury. Front Neurol 6: 73.
• Ellison S, Pardridge WM (1990) Red cell phenylalanine is not available for transport through the blood-brain barrier. Neurochem Res 15: 769–772.
• Fenstermacher JD, Blasberg RG, Patlak CS (1981) Methods for Quantifying the transport of drugs across brain barrier systems. Pharmacol Ther 14: 217–248.
• Fischer JE, Baldessarini RJ (1971) False neurotransmitters and hepatic failure. Lancet 2: 75–80.
• Gjedde A, Christensen O (1984) Estimates of MichaelisMenten constants for the two membranes of the brain endothelium. J Cereb Blood Flow Metab 4: 241–249.
• Hagenfeldt L, Arvidsson A (1980) The distribution of amino acids between plasma and erythrocytes. Clin Chim Acta 100: 133–141.
• Hargreaves KM, Pardridge WM (1988) Neutral amino acid transport at the human blood-brain barrier. J Biol Chem 263: 19392–19397.
• Holecek M (2010) Three targets of branched-chain amino acid supplementation in the treatment of liver disease. Nutrition 26: 482–490.
• Hommes FA (1989) The role of the blood-brain barrier in the aetiology of permanent brain dysfunction in hyperphenylalaninaemia. J Inherit Metab Dis 12: 41–46.
• Knudsen GM (1994) Application of the double-indicator technique for measurement of blood-brain barrier permeability in humans. Cerebrovasc Brain Metab Rev 6: 1–30.
• Knudsen GM, Pettigrew DP, Clifford SP, Paulson OB (1994) Blood-brain barrier permeability measurements by double-indicator method using intravenous injection. Am J Physiol 266: H987–H999.
• Knudsen GM, Hasselbalch S, Toft PB, Christensen E, Paulson OB, Lou H (1995) Blood-brain barrier transport of amino acids in healthy controls and in patients with phenylketonuria. J Inherit Metab Dis 18: 653–664.
• Knudsen GM, Pettigrew KD, Patlak CS, Hertz MM, Paulson OB (1990) Asymmetrical transport of amino acids across the blood-brain barrier in humans. J Cereb Blood Flow Metab 10: 698–706.
• Knudsen GM, Schmidt J, Almdal T, Paulson OB, Vilstrup H (1993) Passage of amino acids and glucose across the blood-brain barrier in patients with hepatic encephalopathy. Hepatology 17: 987–992.
• Lentner C (1984) Geigy Scientific Tables. Vol. 1. CibaGeigy, Basel, Switzerland. Mahler HR, Cordes EH (1966) Biological Chemistry. Harper & Row, New York, USA. Meier C, Ristic Z, Klauser S, Verrey F (2002) Activation of system L heterodimeric amino acid exchangers by intracellular substrates. EMBO J 21: 580–589.
• Miller LP, Pardridge WM, Braun LD, Oldendorf WH (1985) Kinetic constants for blood-brain barrier amino acid transport in conscious rats. J Neurochem 45: 1427–1432.
• Mizock BA, Sabelli HC, Dubin A, Javaid JI, Poulos A, Rackow EC (1990) Septic encephalopathy. Evidence for altered phenylalanine metabolism and comparison with hepatic encephalopathy. Arch Intern Med 150: 443–449.
• Mori M, Adachi Y, Mori N, Kurihara S, Kashiwaya Y, Kusumi M, Takeshima T, Nakashima K (2002) Doubleblind crossover study of branched-chain amino acid therapy in patients with spinocerebellar degeneration. J Neurol Sci 195: 149–152.
• Möller HE, Weglage J, Wiedermann D, Vermathen P, Bick U, Ullrich K (1997) Kinetics of phenylalanine transport at the human blood-brain barrier investigated in vivo. Brain Res 778: 329–337.
• Novotny EJ Jr, Avison MJ, Herschkowitz N, Petroff OA, Prichard JW, Seashore MR, Rothman DL (1995) In vivo measurement of phenylalanine in human brain by proton nuclear magnetic resonance spectroscopy. Pediatr Res 37: 244–249.
• Pardridge WM (1998) Blood-brain barrier carrier-mediated transport and brain metabolism of amino acids. Neurochem Res 23: 635–644.
• Pardridge WM, Mietus LJ (1982) Kinetics of neutral amino acid transport through the blood-brain barrier of the newborn rabbit. J Neurochem 38: 955–962.
• Pardridge WM, Oldendorf WH (1975) Kinetic analysis of blood-brain barrier transport of amino acids. Biochim Biophys Acta 401: 128–136.
• Pietz J, Kreis R, Rupp A, Mayatepek E, Rating D, Boesch C, Bremer HJ (1999) Large neutral amino acids block phenylalanine transport into brain tissue in patients with phenylketonuria. J Clin Invest 103: 1169–1178.
• Renkin EM (1959) Transport of potassium-42 from blood to tissue in isolated mammalian skeletal muscles. Am J Physiol 197: 1205–1210.
• Schindeler S, Ghosh-Jerath S, Thompson S, Rocca A, Joy P, Kemp A, Rae C, Green K, Wilcken B, Christodoulou J (2007) The effects of large neutral amino acid supplements in PKU: an MRS and neuropsychological study. Mol Genet Metab 91: 48–54.
• Shulkin BL, Betz AL, Koeppe RA, Agranoff BW (1995) Inhibition of neutral amino acid transport across the human blood-brain barrier by phenylalanine. J Neurochem 64: 1252–1257.
• Smith QR, Momma S, Aoyagi M, Rapoport SI (1987) Kinetics of neutral amino acid transport across the bloodbrain barrier. J Neurochem 49: 1651–1658.
• Smith QR, Stoll J (1998) Blood-brain barrier amino acid transport. In: Introduction to the Blood-Brain Barrier: Methodology, Biology and Pathology (Pardridge WM, Ed.). Cambridge University Press, Cambridge, UK. Strauss GI, Knudsen GM, Kondrup J, Møller K, Larsen FS (2001) Cerebral metabolism of ammonia and amino acids in patients with fulminant hepatic failure. Gastroenterology 121: 1109–1119.
• Taudorf S, Berg RMG, Bailey DM, Møller K (2009) Cerebral blood flow and oxygen metabolism measured with the Kety-Schmidt method using nitrous oxide. Acta Anaesthesiol Scand 53: 159–167.
• Zinnanti WJ, Lazovic J, Griffin K, Skvorak KJ, Paul HS, Homanics GE, Bewley MC, Cheng KC, Lanoue KF, Flanagan JM (2009) Dual mechanism of brain injury and novel treatment strategy in maple syrup urine disease. Brain 132: 903–918.